"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along ...

EMA's acceptance of Anktiva's application marks a significant step for NMIBC treatment in Europe, following FDA approval in the US. The QUILT 3.032 trial showed a 71% complete response rate for ...

Black men often cite not being asked as the primary reason for not participating in prostate cancer clinical trials. Only 10.4% of surveyed Black men with prostate cancer had participated in clinical ...

"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...

Urology Coding Q&A: Can G2211 be reported regardless of payer?